Palivizumab

A humanized monoclonal antibody that provides passive immunity against RSV. It is specifically used for premature infants and those with congenital heart or lung disease during RSV season.

Dosage by Body Weight

Pediatric dose: 15 mg/kg administered once monthly during the RSV season (usually 5 months).

Body Weight
3-5 kg
Dose
45 mg to 75 mg
Frequency
Monthly
Tracking Notes
Administer intramuscularly, preferably in the anterolateral aspect of the thigh.
Body Weight
6-10 kg
Dose
90 mg to 150 mg
Frequency
Monthly
Tracking Notes
Injection volume > 1 mL should be given as divided doses.

Weight-based dosage tracking table for Palivizumab, including body weight, dose, frequency, and tracking notes.
Body Weight	Dose	Frequency	Tracking Notes
3-5 kg	45 mg to 75 mg	Monthly	Administer intramuscularly, preferably in the anterolateral aspect of the thigh.
6-10 kg	90 mg to 150 mg	Monthly	Injection volume > 1 mL should be given as divided doses.

Formulation

Injection

Purpose

Prevention of serious lower respiratory tract disease caused by Respiratory Syncytial Virus (RSV) in high-risk infants.

Generic Name

Palivizumab

Branded Drug Names

Palivizumab is listed as a generic drug name. Common branded medicines that may contain the same active ingredient include:

Synagis

Scheduled Drug

Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.

Alternatives

Nirsevimab